Personalized therapy for interstitial lung diseases in caused by ABCA3 mutations
5PSQ-135
NEW SECURITY WARNINGS FOR TOFACITINIB: ANALYSIS OF PATIENTS IN RISK
5PSQ-133
ANALYSIS OF REAL-LIFE DATA: OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL OF NIVOLUMAB AND ATEZOLIZUMAB IN NOT SMALL CELLS LUNG CANCER
5PSQ-130
DOSE BANDING OF INTRAVENOUS 5-FLUOROURACIL, OXALIPLATIN, PACLITAXEL AND GEMCITABIN: EVALUATION OF EFFICIENCY AND SAFETY SUBSEQUENT TO AN IMPLEMENTATION PROGRAMME
5PSQ-111
PHARMACEUTICAL INTERVENTION: AVOIDING INTERACTIONS BETWEEN ANTIRETROVIRALS AND VITAMIN SUPPLEMENTS/ ANTIACIDS
5PSQ-108
SECURIZING OF TISAGENLECLEUCEL (KYMRIAH®) STORAGE
5PSQ-107
SECURIZING OF TISAGENLECLEUCEL THAWING AND DELIVERING
5PSQ-106
IMPLEMENTATION OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP) RECONSTITUTION IN A UNIVERSITY TEACHING HOSPITAL IN FRANCE : PROPOSAL OF A DECISION-MAKING ALGORITHM
5PSQ-103
DEVELOPMENT AND TESTING OF A SMARTPHONEBASED SOLID ORAL DOSAGE FORM IMAGE RECOGNITION SYSTEM BY MACHINE LEARNING TO SUPPORT THE IDENTIFICATION OF DISPENSING ERRORS
5PSQ-097
USE AND PERSISTENCE OF FIRST-LINE BIOLOGICAL TREATMENTS FOR PSORIASIS
5PSQ-094
REASONS FOR DISCONTINUATION OF SELECTIVE IMMUNOSUPPRESSIVE BIOLOGICAL TREATMENTS AGAINST PSORIASIS
5PSQ-090
USE OF MONOCLONAL ANTIBODIES AGAINST THE CALCITONIN GENERELATED PEPTIDE PATHWAY IN CHRONIC MIGRAINE IN CLINICAL PRACTICE
5PSQ-088
ANTI SARS-CoV-2 MONOCLONAL ANTIBODIES: FROM CLINICAL TRIAL TO REAL WORLD EVIDENCE
5PSQ-086
EVALUATION OF THE EFFECTIVENESS OF BEZLOTOXUMAB ON PREVENTION OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION
